![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » Drug & Device Pipeline News
Drug & Device Pipeline News
April 10, 2023
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Trials Authorized | |||
Perfuse Therapeutics | PER-001 Intravitreal Implant | Glaucoma | IND for a phase 1/2a trial approved by the FDA |
Trials Initiated | |||
Avacta Group | AVA6000 | Soft tissue sarcoma | Initiation of a phase 1 trial |
Deka Biosciences | DK210 (EGFR) | EGFR- expressing advanced solid tumors | Initiation of a phase 1 trial |
Kodiak Sciences | KSI-501 | Diabetic macular edema | Initiation of a phase 1 trial |
Mythic Therapeutics | MYTX-011 | Non-small cell lung cancer | Initiation of a phase 1 trial |
Y-mAbs Therapeutics | GD2-SADA | GD2-positive solid tumors, including small cell lung cancer, sarcoma and malignant melanoma | Initiation of a phase 1 trial |
Alzamend Neuro | ALZN002 immunotherapy vaccine | Mild-to-moderate Alzheimer’s dementia | Initiation of a phase 1/2a trial |
Contrafect | Exebacase | Chronic prosthetic joint infections of the knee due to Staphylococcus aureus or coagulase-negative staphylococci | Initiation of a phase 1b/2 trial |
Invivyd | VYD222 | COVID-19 | Initiation of a phase 1 trial in Australia |
Vico Therapeutics | VO659 | Huntington's disease and spinocerebellar ataxia types 1 and 3 | Initiation of a phase 1/2a trial in the Netherlands |
Astrocyte Pharmaceuticals | AST-004 | Stroke and traumatic brain injuries | Initiation of a phase 1b trial in the Netherlands |
Vaxcyte | VAX-24 (24-valent pneumococcal conjugate vaccine) | Invasive pneumococcal disease in infants | Initiation of a phase 2 trial |
Sustained Therapeutics | ST-01 | Chronic scrotal pain | Initiation of a phase 2 trial in Canada |
Abcuro | ABC008 | Inclusion body myositis | Initiation of a phase 2/3 trial |
Arrowhead Pharmaceuticals | Fazirsiran (TAK-999/ARO-AAT) | Alpha-1 antitrypsin deficiency associated liver disease | Initiation of a phase 3 trial |
Approvals | |||
InflaRx | Gohibic (vilobelimab) | Hospitalized adults with COVID-19 | Emergency Use Authorization granted by the FDA |
Astellas Seagen |
Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) | Locally advanced or metastatic urothelial cancer | Accelerated approval granted by the FDA |
Synapse Biomedical | NeuRx Diaphragm Pacing System | Patients with spinal cord injuries who rely on mechanical ventilation | Approved by the FDA |
![To view more CenterWatch Weekly stories, click here.](https://no-cache.hubspot.com/cta/default/4532008/07345fb0-4711-43d9-b045-10bbf88744d8.png)
Upcoming Events
-
21Oct